Belshe, R B <br/><br/>
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.  [electronic resource] 

 -  AIDS (London, England)  Dec 1998 
 - 2407-15 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0269-9370 
<br/><br/><label>Standard No.: </label>10.1097/00002030-199818000-00009  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>AIDS Vaccines--adverse effects<br/>Adolescent<br/>Adult<br/>Avipoxvirus--immunology<br/>CD8-Positive T-Lymphocytes<br/>Double-Blind Method<br/>HIV Antibodies--blood<br/>HIV Envelope Protein gp120--immunology<br/>HIV Infections--prevention & control<br/>HIV-1--immunology<br/>Humans<br/>Immunization Schedule<br/>Middle Aged<br/>Neutralization Tests<br/>Peptide Fragments--immunology<br/>Prospective Studies<br/>T-Lymphocytes, Cytotoxic--immunology<br/>Vaccines, Synthetic